INT13075

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 1991
Last Reported 1997
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 0.12
Pain Relevance 2.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NKX2-1) anatomical structure formation involved in morphogenesis (NKX2-1) nucleus (NKX2-1)
DNA binding (NKX2-1)
NKX2-1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 11 100.00 Very High Very High Very High
agonist 8 99.66 Very High Very High Very High
substance P 19 95.44 Very High Very High Very High
qutenza 6 91.64 High High
Neuropeptide 4 89.56 High High
Potency 3 85.68 High High
c fibre 1 72.88 Quite High
Inflammation 3 63.12 Quite High
tetrodotoxin 1 46.80 Quite Low
Central nervous system 1 25.00 Low Low
Disease Link Frequency Relevance Heat
INFLAMMATION 2 63.12 Quite High
Shock 1 57.04 Quite High
Dyspnea 1 40.96 Quite Low
Cough 1 40.24 Quite Low
Disease 2 5.00 Very Low Very Low Very Low
Asthma 2 5.00 Very Low Very Low Very Low
Neurogenic Inflammation 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The compound binds with low nanomolar affinity and species specificity to human NK-1 and NK-2 receptors as well as to guinea pig NK-3 receptors.
NK-2 Binding (binds) of
1) Confidence 0.05 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8627566 Disease Relevance 0.06 Pain Relevance 0.26
The determination of receptor types involved in the effects of tachykinins in the airways has been done with synthetic agonists and antagonists binding specifically to NK-1, NK-2 and NK-3 receptors.
NK-2 Binding (binding) of associated with antagonist and agonist
2) Confidence 0.04 Published 1991 Journal Life Sci. Section Abstract Doc Link 1660952 Disease Relevance 0.06 Pain Relevance 0.45
Experiments with the putative NK-1 (L668, 169) or NK-2 (MEN 10,207, MEN 10,376, L659,877, and R396) selective antagonists against NK-1 and NK-2 selective agonists further supported this conclusion.
NK-2 Binding (Experiments) of associated with antagonist and agonist
3) Confidence 0.02 Published 1991 Journal Am. Rev. Respir. Dis. Section Abstract Doc Link 1713430 Disease Relevance 0 Pain Relevance 0.33
Experiments with the putative NK-1 (L668, 169) or NK-2 (MEN 10,207, MEN 10,376, L659,877, and R396) selective antagonists against NK-1 and NK-2 selective agonists further supported this conclusion.
NK-2 Binding (Experiments) of associated with antagonist and agonist
4) Confidence 0.02 Published 1991 Journal Am. Rev. Respir. Dis. Section Abstract Doc Link 1713430 Disease Relevance 0 Pain Relevance 0.32
MDL 105,172A ((R)-1-[3-(3,4-dicholorophenyl)-1-(3,4,5-trimethoxybenzoyl)- 3-pyrrolidinyl]-4- phenyl-piperidine-4-morpholinecarboxamide) exhibited high affinity for NK-1 (4.34 nM) and NK-2 (2.05 nM) receptors.
NK-2 Binding (affinity) of
5) Confidence 0.01 Published 1997 Journal J Auton Pharmacol Section Abstract Doc Link 9234081 Disease Relevance 0 Pain Relevance 0.28
Senktide, eledoisin, [Lys5,MeLeu9,Nle10]-NKA(4-10), CP 96345, RP 67580, MDL 29913, SR 48968 and Gpp[NH]p were ineffective competitors, suggesting a lack of binding to conventional NK-1, NK-2 or NK-3 receptors.
NK-2 Binding (binding) of
6) Confidence 0.01 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7824047 Disease Relevance 0 Pain Relevance 0.45

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox